NasdaqGM:ZLABBiotechs
Is Positive ALKIVIA Myositis Data for VYVGART Hytrulo Altering The Investment Case For Zai Lab (ZLAB)?
Zai Lab and argenx previously reported positive topline Phase 3 ALKIVIA results for VYVGART Hytrulo in adults with autoimmune myositis, showing a statistically significant and clinically meaningful improvement in Total Improvement Score over 52 weeks versus placebo with a safety profile consistent with earlier studies.
This success in a disease area with no approved targeted therapies highlights the potential for FcRn inhibition to reshape treatment options across difficult-to-treat...